A Comparison of the Diagnostic Sensitivity of MRI, CBF-SPECT, FDG-PET and Cerebrospinal Fluid Biomarkers for Detecting Alzheimer’s Disease in a Memory Clinic
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background/Aim: Magnetic resonance imaging (MRI), cerebral blood flow single photon emission computed tomography (CBF-SPECT), fluorodeoxyglucose-positron emission tomography (FDG-PET) and cerebrospinal fluid (CSF) biomarkers are used for the diagnosis of Alzheimer’s disease (AD). We aimed to reveal the relative sensitivity of these tools in a memory clinic setting. Methods: In 207 patients with probable AD in our memory clinic, medial temporal lobe atrophy on MRI, hypoperfusion/hypometabolism of the parietotemporal lobe and posterior cingulate gyrus in ethylcysteinate dimer-CBF-SPECT/FDG-PET, and abnormalities of CSF amyloid β-protein 1–42, total tau and phosphorylated tau were evaluated as findings characteristic of AD. Results: The AD findings were observed in 77.4% of all AD patients with MRI, 81.6% with CBF-SPECT, 93.1% with FDG-PET and 94.0% with CSF biomarkers. At the stage of Clinical Dementia Rating (CDR) 0.5, CSF biomarkers were the most sensitive (90.0%); at the stage of CDR 1, FDG-PET (96.7%) and CSF biomarkers (95.5%) were highly sensitive. At the stage of CDR 2, all tools showed high positive percentages. Conclusion: The diagnosis of AD was most often supported by CSF biomarkers and FDG-PET at the early stage of dementia (CDR 1) and by CSF biomarkers at the earlier stage (CDR 0.5).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“CSF biomarkers for AD include an increase in total tau (t-tau) and phosphorylated tau (p-tau) and a decrease in amyloid β-protein 1–42 (Aβ42) [”
BackgroundJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340
Self-citationLangbaum, J. B. S., Chen, K., Lee, W., Reschke, C., Bandy, D., Fleisher, A. S., Alexander, G. E., Foster, N. L., Weiner, M. W., Koeppe, R. A., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.12.072 · Cited by 279
Chou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.015 · Cited by 117 · cited 1×
“Comparative studies with these tools reported that lower Aβ42 levels in the CSF were correlated with lateral ventricular expansion [”
ResultBrain FDG PET study of normal aging in Japanese: effect of atrophy correction
Yanase, D., Matsunari, I., Yajima, K., Chen, W., Fujikawa, A., Nishimura, S., Matsuda, H., & Yamada, M. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1767-2 · Cited by 104
Self-citation
Cited by
A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications
James, M. L., & Gambhir, S. S. (2012) · Physiological Reviews · doi:10.1152/physrev.00049.2010 · Cited by 1,140
Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer’s disease
Strom, A., Iaccarino, L., Edwards, L., Lesman-Segev, O. H., Soleimani-Meigooni, D. N., Pham, J., Baker, S. L., Landau, S. M., Jagust, W. J., Miller, B. L., et al. (2022) · Brain · doi:10.1093/brain/awab294 · Cited by 91
Pan, P. L., Song, W., Yang, J., Huang, R., Chen, K., Gong, Q. Y., Zhong, J. G., Shi, H. C., & Shang, H. F. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000338176 · Cited by 90
Soucy, J.-P., Bartha, R., Bocti, C., Borrie, M., Burhan, A. M., Laforce, R., & Rosa-Neto, P. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt199 · Cited by 25
Metadata
- Authors
- Morinaga, A., Ono, K., Ikeda, T., Ikeda, Y., Shima, K., Noguchi-Shinohara, M., Samuraki, M., Yanase, D., Yoshita, M., Iwasa, K., Mastunari, I., & Yamada, M.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 30
- Issue
- 4
- Pages
- 285-292
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W1997289724
- Cited by
- 50
- References
- 9
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comparison of the Diagnostic Sensitivity of MRI, CBF-SPECT, FDG-PET and Cerebrospinal Fluid Biomarkers for Detecting Alzheimer’s Disease in a Memory Clinic. https://app.cochat.ai/papers/10.1159/000320265
- The paper
- Morinaga, A., Ono, K., Ikeda, T., Ikeda, Y., Shima, K., Noguchi-Shinohara, M., Samuraki, M., Yanase, D., Yoshita, M., Iwasa, K., Mastunari, I., & Yamada, M. (2010). A Comparison of the Diagnostic Sensitivity of MRI, CBF-SPECT, FDG-PET and Cerebrospinal Fluid Biomarkers for Detecting Alzheimer’s Disease in a Memory Clinic. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000320265
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.